PTC will acquire controversial DMD drug | Chemical & Engineering News
Volume 95 Issue 12 | p. 13 | Concentrates
Issue Date: March 20, 2017

PTC will acquire controversial DMD drug

Department: Business
Keywords: rare disease, Duchenne muscular dystrophy, drug pricing

PTC Therapeutics has agreed to acquire the Duchenne muscular dystrophy (DMD) treatment Emflaza from Marathon Pharmaceuticals for $140 million plus potential milestone payments. Marathon won FDA approval for Emflaza on Feb. 9 and immediately stirred controversy by pricing it at $89,000 per year, even though it is based on the generic steroid deflazacort. The firm subsequently paused the launch. PTC, which already markets the DMD treatment ataluren in Europe, says it is finalizing commercialization plans.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment